Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

ompound miravirsen, the International Nonproprietary Name (INN) or generic name for the compound formerly known as SPC3649.

Miravirsen, the first microRNA-targeted drug to enter human clinical trials, is a specific inhibitor of miR-122, a liver-specific microRNA that the Hepatitis C virus requires for replication. Unlike Hepatitis C therapies that directly target the virus, miravirsen works by removing a "helper" molecule (miR-122) that the virus needs in order to make new copies. Miravirsen is being studied in a Phase 1 trial multiple-ascending dose study in healthy volunteers and a Phase 2 study in patients infected with Hepatitis C is expected to begin in the second half of 2010.

Santaris Pharma A/S also has a broad range of drug discovery and development programs with its partners: Shire plc (lead candidates against up to five targets for rare genetic disorders), Pfizer (lead candidates against up to ten targets), GlaxoSmithKline (options to drug candidates from up to four viral disease programs) and Enzon Pharmaceuticals (lead candidates against eight cancer targets successfully delivered).

About Locked Nucleic Acid (LNA) Drug Platform

The LNA Drug Platform utilizing Santaris Pharma A/S proprietary LNA chemistry provides the key to delivering on the promise of RNA-targeted therapies today by addressing these concerns and overcoming the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity, which is only achievable with LNA-based drugs, allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. LNA-based drugs are a promising new type of therapy that enables scientists to develo
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  ISN has released its third annual U.S. ... publication series. With data aggregated from over eight billion ... its online contractor management platform, ISNetworld, this three-part series ... statistics. The Contractor Performance ... available in two industry specific volumes: Oil & ...
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... Bellingham, Washington, USA (PRWEB) December 16, 2014 ... Kirstin Baum, manager at Philipps- Universität Marburg’s Department ... optics and photonics, in the newly released ... 2015-2016. “And never be too shy to ask ... STEM (science, technology, engineering, and mathematics) occupations ranging ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... 20 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... interpretation services,announced today that Dr. Michael J. McKelvey, ... Baron, the Company,s Chief Financial,Officer, are scheduled to ... at 9:00 a.m. Eastern on May 28, 2008 ...
... Parents of children with,autism often grapple with a bewildering ... the disorder? Could it be genetic? What is it,like to ... therapies that,might alleviate some of my child,s symptoms?", On ... will have a unique opportunity to hear from researchers on ...
... on Regenesis, SCOTTSDALE, Ariz., May 20 ... the Provant(R) Wound Therapy,System, announced today the formation ... to guide advanced scientific investigations into the,mechanism of ... of Regenesis, platform technology to clinical and industrial,applications., ...
Cached Biology Technology:eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008 2First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 2First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 3Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... of us never considered eating the mud pies we made ... dining on dirt is nothing out of the ordinary. Now ... The Quarterly Review of Biology helps explain why. ... human geophagythe eating of earthis that it protects the stomach ...
... a researcher, please contact the Communications and External Relations staff member ... ORNL and its research and development activities, please refer to one ... or comment, you can send it to news@ornl.gov . ... Unsafe commercial motor vehicles may be off the ...
... like a computer. An organism,s genome is the software ... do. But instead of electronic circuitry, life relies on ... organisms to function. Now, researchers at the California Institute ... circuit ever created from scratch, made with DNA-based devices ...
Cached Biology News:Eating dirt can be good for the belly, researchers find 2Eating dirt can be good for the belly, researchers find 3Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2011 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 3Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 4
golgi reassembly stacking protein 2, 55kDa...
...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Reactivity: Human...
Biology Products: